Categories: News

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

November 20, 2023

Please see attachment.

Contact information

Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com

Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com

Attachment

Staff

Published by

Staff

2 years ago

TempraMed Enters Strategic Media Partnership with Dr. Phil’s Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States

Access to an audience of over 19 million individuals monthly will expand national exposure, and…

1 hour ago

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

19 hours ago

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

19 hours ago

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

2 days ago

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

2 days ago

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

2 days ago